Anticancer agent 272
Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC50: 2.81 μM) . Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (•OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Ferroptosis; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Smiles
BrC1=CN=C(N2[N]([Cu+2]34([Cl-][Cu+2]5([Cl-])([Cl-]4)[N](N6C7=NC=C(C=[N]75)Br)=C(C=C6C(C)C)C(C)C)[Cl-])=C(C=C2C(C)C)C(C)C)[N]3=C1
Molecular Formula
C26H34Br2Cl4Cu2N8
Molecular Weight
887.31
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
COL11A1 Lentiviral Activation Particles (h2)
Pgpep1 sgRNA CRISPR Lentivector (Mouse) (Target 2)